Literature DB >> 14727876

Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release.

J A Schrier1, P P DeLuca.   

Abstract

This research compared the binding and release of recombinant human bone morphogenetic protein 2 (rhBMP-2) with a series of hydrophobic and hydrophilic poly-lactide-co-glycolide (PLGA) copolymers. Porous microspheres were produced via a double emulsion process. Binding and incorporation of protein were achieved by soaking microspheres in buffered protein solutions, filtering, and comparing protein concentration remaining to nonmicrosphere-containing samples. Protein release was determined by soaking bound microspheres in a physiological buffer and measuring protein concentration (by reversed-phase high-performance liquid chromatography) in solution over time. Normalized for specific surface area and paired by polymer molecular weight, microspheres made from hydrophilic 50:50 or 75:25 PLGA bound significantly more protein than microspheres made from the corresponding hydrophobic PLGA. Increased binding capacity correlated with higher polymer acid values. With certain polymers, rhBMP-2 adsorption was decreased or inhibited at high protein concentration, but protein loading could be enhanced by increasing the protein solution:PLGA (volume:mass) ratio or by repetitive soaking. Microspheres of various PLGAs released unbound protein in 3 days, whereas the subsequent bound protein release corresponded to mass loss. RhBMP-2 binding to PLGA was controlled by the acid value, protein concentration, and adsorption technique. The protein released in 2 phases; the first occurred over 3 days regardless of PLGA used and emanated from unbound, incorporated protein, while the second was controlled by mass loss and therefore was dependent on the polymer molecular weight. Overall, control of rhBMP-2 delivery is achievable by selection of PLGA microsphere carriers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 14727876      PMCID: PMC2750582          DOI: 10.1208/pt020317

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  16 in total

1.  Stability of the thrombolytic protein fibrolase: effect of temperature and pH on activity and conformation.

Authors:  D Pretzer; B S Schulteis; C D Smith; D G Vander Velde; J W Mitchell; M C Manning
Journal:  Pharm Res       Date:  1991-09       Impact factor: 4.200

2.  Recombinant bone morphogenetic protein-2 enhances bone healing, guided by osteopromotive e-PTFE membranes: an experimental study in rats.

Authors:  A Linde; E Hedner
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

3.  Principles of tissue engineering applied to programmable osteogenesis.

Authors:  J H Brekke; J M Toth
Journal:  J Biomed Mater Res       Date:  1998

4.  The evaluation of lyophilized polymer matrices for administering recombinant human bone morphogenetic protein-2.

Authors:  S S Duggirala; J B Rodgers; P P DeLuca
Journal:  Pharm Dev Technol       Date:  1996-07       Impact factor: 3.133

5.  Ectopic induction of cartilage and bone by water-soluble proteins from bovine bone using a collagenous delivery vehicle.

Authors:  P A Lucas; G T Syftestad; V M Goldberg; A I Caplan
Journal:  J Biomed Mater Res       Date:  1989-04

6.  Recombinant human bone morphogenetic protein-2 binding and incorporation in PLGA microsphere delivery systems.

Authors:  J A Schrier; P P DeLuca
Journal:  Pharm Dev Technol       Date:  1999       Impact factor: 3.133

Review 7.  Biotechnology and bone graft substitutes.

Authors:  R A Kenley; K Yim; J Abrams; E Ron; T Turek; L J Marden; J O Hollinger
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

Review 8.  Strategies for regenerating bone of the craniofacial complex.

Authors:  J Hollinger
Journal:  Bone       Date:  1993 May-Jun       Impact factor: 4.398

9.  Acid-catalyzed peptide bond hydrolysis of recombinant human interleukin 11.

Authors:  R A Kenley; N W Warne
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

10.  Degradation pathways for recombinant human macrophage colony-stimulating factor in aqueous solution.

Authors:  J A Schrier; R A Kenley; R Williams; R J Corcoran; Y Kim; R P Northey; D D'Augusta; M Huberty
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

View more
  4 in total

Review 1.  Growth factor delivery: how surface interactions modulate release in vitro and in vivo.

Authors:  William J King; Paul H Krebsbach
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

2.  Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix.

Authors:  B H Woo; B F Fink; R Page; J A Schrier; Y W Jo; G Jiang; M DeLuca; H C Vasconez; P P DeLuca
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

3.  Effect of a freeze-dried CMC/PLGA microsphere matrix of rhBMP-2 on bone healing.

Authors:  J A Schrier; B F Fink; J B Rodgers; H C Vasconez; P P DeLuca
Journal:  AAPS PharmSciTech       Date:  2001-10-07       Impact factor: 3.246

4.  Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2.

Authors:  Zarana S Patel; Masaya Yamamoto; Hiroki Ueda; Yasuhiko Tabata; Antonios G Mikos
Journal:  Acta Biomater       Date:  2008-04-22       Impact factor: 8.947

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.